Tazemetostat (EPZ-6438)
99%
- Product Code: 102805
CAS:
1403254-99-8
| Molecular Weight: | 572.74 g./mol | Molecular Formula: | C₃₄H₄₄N₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD24849415 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Tazemetostat is primarily used in the treatment of certain types of cancer, particularly those associated with mutations in the EZH2 gene. It functions as an inhibitor of EZH2, a protein involved in the regulation of gene expression. By blocking EZH2, tazemetostat helps to restore normal gene activity, which can slow down or stop the growth of cancer cells.
One of the key applications of tazemetostat is in the treatment of epithelioid sarcoma, a rare and aggressive soft tissue cancer. It is specifically indicated for patients whose tumors have lost the INI1/SMARCB1 gene, a condition that makes the cancer more dependent on EZH2 activity. Tazemetostat has shown promise in providing a therapeutic option for these patients, particularly when surgery is not feasible.
Additionally, tazemetostat is being investigated for use in other cancers, such as non-Hodgkin lymphoma, where EZH2 mutations are also prevalent. Clinical trials are ongoing to explore its efficacy in these and other malignancies, potentially expanding its application in oncology.
Overall, tazemetostat represents a targeted approach to cancer treatment, offering hope for patients with specific genetic alterations in their tumors.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | White To Off-White Solid |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿4,290.00 |
+
-
|
| 0.025 | 10-20 days | ฿7,690.00 |
+
-
|
Tazemetostat (EPZ-6438)
Tazemetostat is primarily used in the treatment of certain types of cancer, particularly those associated with mutations in the EZH2 gene. It functions as an inhibitor of EZH2, a protein involved in the regulation of gene expression. By blocking EZH2, tazemetostat helps to restore normal gene activity, which can slow down or stop the growth of cancer cells.
One of the key applications of tazemetostat is in the treatment of epithelioid sarcoma, a rare and aggressive soft tissue cancer. It is specifically indicated for patients whose tumors have lost the INI1/SMARCB1 gene, a condition that makes the cancer more dependent on EZH2 activity. Tazemetostat has shown promise in providing a therapeutic option for these patients, particularly when surgery is not feasible.
Additionally, tazemetostat is being investigated for use in other cancers, such as non-Hodgkin lymphoma, where EZH2 mutations are also prevalent. Clinical trials are ongoing to explore its efficacy in these and other malignancies, potentially expanding its application in oncology.
Overall, tazemetostat represents a targeted approach to cancer treatment, offering hope for patients with specific genetic alterations in their tumors.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :